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Available online 30 June 2016Background: Ovarian cancer patients have a high risk of developing venous thrombosis. The membrane lipid
bilayer of platelets and platelet-derived microparticles (PMP) provides a platform for assembly of coagulation
proteins and generation of blood clots.
Methods:We compared the lipid composition of platelets and PMPs in patients with ovarian cancer to those in
healthy subjects. We used shotgun lipidomics to quantify 12 classes and 177 species of lipids.
Results:We found a signiﬁcant change in 2 classes of lipids in platelets and PMPs isolated from ovarian cancer
patients: higher phosphatidylinositol and lower lyso-phosphatidylcholine. The level of 28 species of lipids was
also signiﬁcantly altered in the direction of an increase in the pro-coagulant and a reduction in the anticoagulant
lipids. We found that cancer platelets expressed less lipid phosphate phosphatase 1 (LPP1), a key enzyme in
phospholipid biosynthesis pathways, than normal platelets. The reduction in LPP1 might contribute to the
changes in the lipid proﬁle of cancer platelets.
Conclusion: Our results support a procoagulant lipid proﬁle of platelets in ovarian cancer patients that can play a
role in the increased risk of venous thrombosis in these patients.
General signiﬁcance: As far as we are aware, our study is the ﬁrst study on platelet lipidomics in ovarian cancer.
The importance of our ﬁndings for the future studies are: 1) a similar change in lipid proﬁle of platelets and
PMPmay be responsible for hypercoagulability in other cancers, and 2) plasma level of high-risk lipids for venous
thrombosis may be useful biomarkers.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Lipid phosphate phosphatase 11. Introduction
Hypercoagulability, an activated state of coagulation that can be
detected in a majority of cancer patients [6,17,28], can remain as a sub-
clinical condition or results in thrombosis. Venous thromboembolism
(VTE) is a challenging complication ofmalignancy and the second leading
cause of death in cancer patients. Several studies have identiﬁed a variety
of risk factors for VTE [9], however, the exact molecular mechanisms for
the cancer-associated hypercoagulable state and venous thrombosis re-
main unknown.
Coagulation is theﬁnal result of a close interaction between coagula-
tion cascade and platelet membrane. Membrane lipids of activated
platelets, particularly phosphatidylserine (PS), mediate binding andod@mdanderson.org
. This is an open access article underassembly of coagulation factors, which in turn promote generation
of thrombin and ﬁbrin. Other lipids in the platelet membrane
interact with PS, and have regulatory roles as either procoagulant or an-
ticoagulant lipids [24]. Phosphatidylinositol (PI), phosphatidic acid
(PA), and phosphatidylglycerol (PG) were demonstrated to be
procoagulants; while phosphatidylcholine (PC), acyl-carnitines (CAR)
[4], and sphingomyelins (SM) [12] are anticoagulants. The effect of the
other lipid classes on coagulation is not clear. The role of ceramides
(CER) in platelet function is uncertain [16]. Cardiolipins (CL) are almost
exclusively present in mitochondria [5]. The net effect of phosphatidyl-
ethanolamines (PE) on coagulation is hard to assess because initially PE
synergizeswith PS to promote coagulation, but later inactivates FVa [19,
20]. Lyso-PE (LPE) have not been reported to be involved in coagulation.
There are controversial reports on the role of LPCs in coagulation [25].
Each of these lipid classes includes several lipid species. Lipid species
within a lipid class have similar structural features and usually similar
functional roles in coagulation [24,25]. Activated platelets also releasethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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microparticles (PMP), that are highly procoagulant and can initiate and
propagate coagulation [22]. In cancer patients, the crosstalk between
platelets and cancer cells results in platelet activation and in a repertoire
of molecular changes in platelets and cancer cells [2]. We speculated
that cancer-related changes in platelet composition of molecules, and
consequently in PMPs, might contribute to a hypercoagulable state and
increased risk of thrombosis in cancer patients. We compared the lipid
content of platelets and PMPs in patients with ovarian cancer to that in
healthy controls. We identiﬁed alterations in lipid content of platelets
and PMPs in cancer patients at both lipid class and species levels, with a
majority of changes in the direction of promoting coagulation. Further-
more, we found that microparticle generation by cancer patients' and
healthy subjects' platelets result in a similar pattern of enrichment of
the lipids content in PMPs.
2. Materials and methods
All of the studieswere approved by the Institutional ReviewBoard of
TheUniversity of TexasM. D. Anderson Cancer Center and in accordance
with an assurance approved by the US Department of Health and
Human Services.
2.1. Reagents
Chloroform,methanol, and isopropanol were purchased from Burdick
and Jackson (Muskegon, MI). Lithium chloride and lithium hydroxide
were obtained from Sigma-Aldrich Chemical Co. (St. Louis, MO). All of
the lipid internal standards were purchased from Avanti Polar Lipids,
Inc. (Alabaster, AL) unless otherwise indicated. 1,2-Dimyristoleoyl-sn-
glycero-3-phosphocholine (di14:1 PC); 1,2-Dipalmitoleoyl-sn-glycero-3-
phosphoethanolamine (di16:1 PE); 1,2-Dipentadecanoyl-sn-glycero-3-
phosphoglycerol (sodium salt) (di15:0 PG); 1,2-Dimyristoyl-sn-glycero-
3-phospho-L-serine (sodium salt) (di14:0 PS); 1,2-Dimyristoyl-sn-
glycero-3-phosphate (sodium salt) (di14:0 PA); 1,1′,2,2′-Tetramyristoyl
cardiolipin (T14:0 CL); N-Lauroyl sphingomyelin (N12:0 SM); N-
Heptadecanoyl ceramide (N17:0 Cer); 1-Heptadecanoyl-2-hydroxy-sn-
glycero-3-phosphocholine (17:0 lysoPC); 1,2,3,4-13C4-Palmitoyl-L-
carnitine hydrochloride (13C4-16:0 CN) (Sigma-Aldrich, St. Louis, MO).
2.2. Preparation of platelets and microparticles
Washedplateletswere prepared from3patientswith ovarian cancer
and 3 gender and age-matched healthy subjects. Blood samples from
cancer patient were obtained prior to any surgical intervention or
chemotherapy. Patientswith ovarian cancer did not have any detectable
metastasis at the time of blood draw, and had normal blood counts and
normal routine coagulation parameters. Platelets were prepared from
20 mL of fresh whole blood using a previously described method [21].
PMPswere prepared by activating thewashed plateletswith a combina-
tion of thrombin (0.1 unit/mL) and collagen (50 μg/mL) at 37 °C for
30 min, as described before [3,18]. Washed platelets and PMPs were
pelleted and stored at−80 °C for lipidomics.
2.3. Shotgun lipidomics
Both platelets and PMPs were resuspended in 300 μL PBS and
homogenized for 1 min using a disposable soft tissue homogenizer. An
aliquot of 25 μL was pipetted to determine the protein content (BCA
protein assay kit, Thermo Scientiﬁc, Rockford, IL). The rest of homoge-
nate was transferred into a disposable glass culture test tube. For quan-
tiﬁcation of all reported lipid species, a mixture of lipid internal
standards was added prior to lipid extraction. Lipid extraction was
performed by a modiﬁed Bligh and Dyer procedure [29]. Each lipid ex-
tract was resuspended into a volume of 500 μL of chloroform/methanol
(1:1, v/v) per mg of protein and ﬂushed with nitrogen, capped, andstored at −20 °C for lipid analysis. For direct infusion electrospray
ionization (ESI) analysis, lipid extract was further diluted to a ﬁnal con-
centration of ~500 fmol/μL, and the mass spectrometric analysis was
performed on a QqQ mass spectrometer (Thermo TSQ VANTAGE, San
Jose, CA) equipped with an automated nanospray device (TriVersa
NanoMate, Advion Bioscience Ltd., Ithaca, NY).
2.4. Western blot analysis
Washed platelets were lyzed in a buffer consisting of 1% Triton X-
100, 50 mM HEPES, pH 7.4, 150 mM NaCl, 1.5 mMMgCl2, 1 mM EGTA,
100 mM NaF, 10 mM Na pyrophosphate, 1 mM Na3VO4, 10% glycerol,
and freshly added protease and phosphatase inhibitors from Roche
Applied Science (Cat. # 05056489001 and 04906837001, respectively).
Protein concentrations of the lysates were determined by a BCA Protein
Reagent Kit (Pierce Biotech.), and 25 μg of proteins were subjected to
gel electrophoresis on 10% SDS-PAGE gels. Antibodies used were
against LPP1 (Abcam, ab198280, at 1:250 dilution), and β-ACTIN
(Sigma-Aldrich, A5316, 1:5000).
2.5. Statistical analysis
All lipid class or species data were expressed as means ± SE for
triplicate measurements. Comparisons between groups were made
using the Student's t-test with p b 0.1 being considered statistically
signiﬁcant. For comparable analysis between platelets and PMPs, the
measured value for a lipid class or a species was converted to parts
per thousand (ppt), or equivalent to nmol per a total of 1000 nmol
lipids. Measured values for lipid classes in platelet and PMP samples
were subjected to multivariate analysis in the form of unsupervised
principal component analysis (PCA), using Partek Genomics Suite 6.6
(Partek, St. Louis, MO). PCA is used to visualize the interrelationship
between large numbers ofmeasured (observed) variables and describes
the largest variation in data using principal components to plot against
each other so that trends and groupings can be detected [10].
3. Results
3.1. Lipid content of platelets/PMPs in ovarian cancer patients and normal
subjects
A total of 12 classes and 177 species of lipids were analyzed by
shotgun lipidomics. The total amount of lipid content of platelets and
PMPs was not different between cancer patients and normal subjects
(Fig. S1A). The total amount of lipid content in PMPs was less than in
platelets, which is expected given the size difference between platelets
and PMPs.
The 2 main lipid classes in both platelets and PMPs were phosphati-
dylethanolamine (PE), including plasmalogen PE (PE-pl), and phospha-
tidylcholine (PC) (Fig. 1), similar to the reported lipid composition of
cell membrane in eukaryotes [26].
Lipid proﬁles (classes and species) of platelets and PMPs were
compared between cancer and control groups. Phosphatidylinositol
(PI) class in PMPs was signiﬁcantly higher (~2-fold) in cancer patients
than in controls, and a similar trend was observed in platelets although
statistically non-signiﬁcant (p=0.20). Lyso-phosphatidylcholine (LPC)
class was ~26% lower in cancer platelets compared to controls (p =
0.09), and a similar trend was observed in PMPs (p= 0.18) (Fig. 1). In
cancer platelets, a trend toward reduction in PC, a precursor of LPC,
was observed.
Changes in lipid species in platelets or PMPs of ovarian cancer
patients as compared to healthy subjects were compiled in Table 1. To
conduct a meaningful comparison of lipid species, we focused on lipid
species in 7 lipid classes with a known regulatory role in coagulation
(PS, PI, PA, PG, PC, CAR, and SM), and eliminated the other 5 lipid classes
(ceramides, cardiolipins, PE, lyso-PE, Lyso-PC) from our analysis. In the
Fig. 1. Lipid class distribution in platelets and PMPs and comparison between the cancer and control groups. Phosphatidylinositol (PI) class content in PMPs from cancer samples was ~2
fold higher than that from the controls with a signiﬁcance level p = 0.01. Lyso-phosphatidylcholine (LPC) class content in platelets from cancer samples was reduced by ~26% at a
signiﬁcance level of 0.09. ** indicates p ≤ 0.01. PE: phosphatidylethanolamine; PC: phosphatidylcholine; PS: phosphatidylserine; CAR: acyl-carnitine; CER: ceramide; LPE: lyso-
phosphatidylethanolamine; CL: cardiolipin; PG: phosphatidylglycerol; PA: phosphatidic acid. CtrPlt: control platelets; CaPlt: cancer platelets; CtrPMP: control PMPs; CaPMP: cancer PMPs.
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Of note, the predominant PI species 18:0–20:4 doubled in PMPs of
cancer patients (Fig. S1B and Table 1). The procoagulant change in a
lipid species is highlighted in red and the anticoagulant change in
green. The procoagulant changes involved ~20% of total species (24
out of 115 species in the 7 lipid classes) (Table 1). Considering different
abundance of lipid species, the procoagulant changes involved 28% of
lipid molecules (179.95 nmol out of 649.27 nmol of the 7 classes of
lipids). The anticoagulant changes involved a residual 0.6% of lipids.
The total pro-coagulant/anti-coagulant lipid ratio was calculated, and
found for cancer platelets to be 0.425 ± 0.401 and for normal platelets
0.395 ± 0.028; the same ratio for cancer and normal PMP was
0.377 ± 0.012, and 0.307 ± 0.049, respectively.
Two out of 5 CAR species, CAR 18:1 and CAR 14:0, were reduced in
PMPs of cancer patients by 1.9-fold (p = 0.07) and 3.2-fold (p =
0.08), respectively. The other 3 CAR species showed downward trend
that was not statistically signiﬁcant; e.g., CAR 20:4 was reduced by 1.9
folds (p= 0.14). Interestingly, in a previous study on venous thrombo-
embolism (VTE) within general population, several species of CARwere
identiﬁed to have lower plasma levels in VTE patients as compared to
control subjects. Further mechanistic study demonstrates that CAR
acts as anticoagulants and inhibits Factor Xa-induced clotting [4].3.2. Lipid enrichment/depletion in PMPs of control subjects and cancer
patients
We compared lipid content of PMPs to those of intact platelets in pa-
tients with ovarian cancer and in healthy subjects. The enriched or
depleted lipid classes or species with p ≤ 0.10 are presented in
Table S1. We found similar pattern but different magnitude of enrich-
ment or depletion of lipids in PMPs from cancer patients and control
subjects. Three out of 12 lipid classes (CAR, PG, PA) were enriched,
and 2 of 12 (PC, PI) were depleted in PMPs (Fig. 2). Additionally, 6
lipid species from PE, PS, and Lyso-PC classes were either enriched or
depleted in PMPs. There was no changes in the lipid species of SM,
CER, PE, CL classes in PMPs (Table S1). Although PMPs from both cancer
patients and controls showed similar and consistent trend but the mag-
nitude of enrichment or depletion of lipid specieswas different between
them. For example, procoagulant PG class was signiﬁcantly enriched in
PMPs from control and cancer groups by 2.2-fold and 3.6-fold,respectively. Anticoagulant CAR class was enriched in PMPs of control
subjects by 2.5 folds (p = 0.06), whereas in cancer patients CAR
increased by 1.4-fold (p= 0.24). The procoagulant class PI depleted in
PMPs of both groups. PMPs in control subjects had a 2-fold decrease
(p = 0.06) in PI, and in cancer patients had a 1.4-fold decrease (p =
0.12). Overall, in cancer patients the procoagulant changes in lipid
content of PMPs were more pronounced, and the anticoagulant
changes were smaller in magnitude as compared to control subjects.
3.3. Distinct lipid proﬁles of platelets and PMPs in cancer patients and
controls
We used principal component analysis (PCA) to summarize and
visualize the large number of data generated by comparing lipid classes
between platelets and PMPs of cancer patients and controls [10]. As a
result, data generated from 6 subjects can be categorized into 4 distinct
groups of cancer platelets, control platelets, cancer PMPs, and controls
PMPs; with clear proximity between same type of samples from different
individual, and little overlap between different groups (Fig. 3.). The ﬁrst
principal component (PC1) accounted for 34.4% of the total variance in
the data and the second principal component explained ~22.1% of the
total. PCA results showed that the differences in lipid proﬁles betweendif-
ferent groups are recurrent and not due to random differences.
3.4. Lipid phosphate phosphatase 1 (LPP1) in platelets of control subjects
and cancer patients
We compared expression of LPP1, a key enzyme in the phospholipid
metabolism, in platelets of ovarian cancer patients to that of healthy
subjects byWestern-blotting. Relative LLP1 protein level wasmeasured
as the ratio of intensity of band representing LPP1 to β-ACTIN in platelet
lysates of 3 patients with ovarian cancer and 3 control subjects. Platelets
from cancer patients showed N50% reduction in the level of LPP1 as
compared to control platelets (0.25 vs 0.11, p = 0.03, n = 3 in each
group) (Fig. 4A and B).
4. Discussion
In this study, we have investigated the effect of ovarian cancer on
lipid proﬁle of platelets, and the effect of platelet microvesiculation on
Table 1
List of lipid class and species with compositional changes in platelets and/or MPs between cancer patients and healthy controls.
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identiﬁed recurrent and persistent changes in lipid composition of
cancer platelets and PMPs. Platelets of cancer patients have a higher
amount of PI class of lipids, lower Lyso-PC, and a similar amount of
phosphatidic acid (PA). In phospholipid metabolism phosphatidic acid
(PA), although comprises only a minute amount of the total amount of
cellular lipid content, plays an important role as the initial substrate in
phospholipids biosynthesis. Lipid phosphate phosphatase 1 (LPP1)
removes a phosphate group from PA to generate diacylglycerol that
can be used for synthesis of phosphatidylcholine (PC). The alternative
route for PA is to be converted to CDP-diacylglycerol to be used for
generation of PI. LPP1 is decreased in the majority of ovarian cancers
[23]. We speculated that a reduction in LPP1 in ovarian cancer platelets
divert limited available PA in platelets away from PC synthesis and
toward PI generation. In fact, our data demonstrated that LPP1 is
reduced by ~56% in cancer platelets. This signiﬁcant reduction in LPP1
might explain the increase in PI in cancer platelets. Lyso-PC is the prod-
uct of hydrolysis of PC and a reduction in Lyso-PC in cancer platelets, as a
part of a trend of PC reduction, was also detected in our study.
In addition to the twomajor classes of lipid, we identiﬁed changes in
28 lipid species (Table 1). Considering the importance of platelets andPMPs lipid bilayer in assembly of coagulation factors and increased
risk of venous thrombosis in ovarian cancer patients, we investigated
the changes in lipid specieswithin lipid classeswith a known regulatory
role in coagulation (PS, PI, PA, PG, PC, CAR, and SM). The other lipid
classes were either strictly mitochondrial and were physically distant
from coagulation factors or did not have a well-established effect on
coagulation. We identiﬁed that the overwhelming majority of changes
in lipid species in cancer platelets were toward an increase in
procoagulant lipids and a reduction in anticoagulant lipids. Although
the trend toward more procoagulant and less anticoagulant lipids in
cancer platelets is important, but perhaps the change in one key lipid
moiety rather than a small amount of change in the total sum of several
procoagulant or anticoagulant lipids can have more clinical impact.
Activation of platelets by various platelet agonists or calcium iono-
phore results in generation of microparticles from platelet surface.
These PMPs are encircled by lipid bilayer and are highly procoagulant.
We compared the lipid content of PMPs with the original platelets and
identiﬁed enrichment and depletion of several procoagulant and antico-
agulant lipid classes and species. Although the procoagulant changes in
lipid proﬁle of PMPs from ovarian cancer patients were more
pronounced than those in normal PMPs, we did not detect an
Fig. 2. Enrichment or depletion of lipid classes in PMPs. Comparison was conducted between PMPs and platelets for both control and cancer samples and 5 classes of lipids displayed
enrichment or depletion in MPs of either or both origins. The numbers on top of the cluster bars are p values for enrichment or depletion. * indicates p ≤ 0.05 and ** indicates p ≤ 0.01.
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We speculate that the increase in the procoagulant activity of PMPs
might be due the change in distribution of lipid classes rather than the
quantity of lipids, i.e. distributionof procoagulant lipids to the outer leaﬂet
of lipid bilayer. Only few studies have investigated the lipid content of
platelets and PMPs in healthy human subjects [15,16]. As far as we are
aware, our study is theﬁrst one comparing lipid proﬁle of platelets in can-
cer patients and normal subjects. Our results demonstrated that the
procoagulant lipids were increased and anticoagulant lipids decreased
in platelets and/or PMPs of cancer patients. Thismight contribute to a hy-
percoagulable state in cancer patients. We recently reported that platelet
of patientswith ovarian cancer are not hyperreactive and have similar ag-
gregation response to platelet agonists as platelets of healthy subjects [7].
This further support the possibility that contribution of cancer platelets to
a hypercoagulable state might be related to an aggregation-independent
effect of platelets in hemostasis via increasing coagulation.
Platelets and PMPs play important role in tumor progression [8,27].
Alteration in the lipid content of platelets, and as a result in the lipid
content of PMPs, may contribute to the progression of ovarian cancer
via an interaction between platelets and cancer cells. Both platelets
and PMPs can fuse to cell membrane and be internalized by cancer
cells [1,13,14]. In addition to their cytoplasmic content, PMPs can alsoFig. 3. PCA score scatter plot indicated distinct categories for the 4 analyzed samples CaPlt,
CaPMP, CtrPlt, and CtrPMP. PC#1: ﬁrst principal component; PC#2: second principal
component.transfer their lipid contents to cancer cells. Elevated concentration of
PI in PMPs can provide a source for synthesis of phosphoinositides and
PI3K signaling molecules in cancer cells, and decrease the relative
concentration of Lyso-PC and PC in these cells. Both Lyso-PC and PC
have been demonstrated to play antitumor roles in lung cancer and
pancreatic cancer murine models, respectively [11].
Crosstalk between platelets and cancer cells can change their com-
positions. It has been shown that tumor cells alter plateletmRNA proﬁle
[2]. Reduction in LPP1 in ovarian cancer cells may result in reduction in
LLP1 and altering phospholipid composition in platelets. Fusion of PMP
and internalization of PMP lipid content into ovarian cancer cells, in
turn, might change the lipid proﬁle of cancer cells.Fig. 4. Platelets of cancer patients expressed less than half of the LPP1 protein of control
platelets. (A) Western blot analysis of LPP1 protein expression level in platelets of both
control subjects and cancer patients. (B) Quantiﬁcation of relative protein expression
level and comparison between the control and cancer groups. Data presented as
mean ± sem.
81Q. Hu et al. / BBA Clinical 6 (2016) 76–81Our study is the ﬁrst study to correlate the presence of cancer with
speciﬁc changes in the lipid composition of platelets. We identiﬁed
potential links between alteration in lipids in platelets and PMPs and
an increased risk of thrombosis or a progrowth effect of platelets on
cancer. These links need to be validated in larger studies and can pro-
vide preliminary information for development of new biomarkers,
such as a low concentration of CAR in plasma PMPs, as predictive of
development of venous thrombosis in cancer patients.
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